These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 28642124)

  • 1. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
    Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ
    Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
    Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
    Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
    Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F
    Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.
    Flower M; Lomeikaite V; Ciosi M; Cumming S; Morales F; Lo K; Hensman Moss D; Jones L; Holmans P; ; ; Monckton DG; Tabrizi SJ
    Brain; 2019 Jun; 142(7):1876-86. PubMed ID: 31216018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
    Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA;
    Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.
    Ciosi M; Maxwell A; Cumming SA; Hensman Moss DJ; Alshammari AM; Flower MD; Durr A; Leavitt BR; Roos RAC; ; ; Holmans P; Jones L; Langbehn DR; Kwak S; Tabrizi SJ; Monckton DG
    EBioMedicine; 2019 Oct; 48():568-580. PubMed ID: 31607598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
    Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation study of Huntington's disease and motor progression in patients and in animal models.
    Lu AT; Narayan P; Grant MJ; Langfelder P; Wang N; Kwak S; Wilkinson H; Chen RZ; Chen J; Simon Bawden C; Rudiger SR; Ciosi M; Chatzi A; Maxwell A; Hore TA; Aaronson J; Rosinski J; Preiss A; Vogt TF; Coppola G; Monckton D; Snell RG; William Yang X; Horvath S
    Nat Commun; 2020 Sep; 11(1):4529. PubMed ID: 32913184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical manifestations of homozygote allele carriers in Huntington disease.
    Cubo E; Martinez-Horta SI; Santalo FS; Descalls AM; Calvo S; Gil-Polo C; Muñoz I; Llano K; Mariscal N; Diaz D; Gutierrez A; Aguado L; Ramos-Arroyo MA;
    Neurology; 2019 Apr; 92(18):e2101-e2108. PubMed ID: 30867264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice.
    Tomé S; Manley K; Simard JP; Clark GW; Slean MM; Swami M; Shelbourne PF; Tillier ER; Monckton DG; Messer A; Pearson CE
    PLoS Genet; 2013; 9(2):e1003280. PubMed ID: 23468640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations of intermediate allele carriers in Huntington disease.
    Cubo E; Ramos-Arroyo MA; Martinez-Horta S; Martínez-Descalls A; Calvo S; Gil-Polo C;
    Neurology; 2016 Aug; 87(6):571-8. PubMed ID: 27402890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
    Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
    Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Analysis of Chromosome X to Identify Genetic Modifiers of Huntington's Disease.
    Hong EP; Chao MJ; Massey T; McAllister B; Lobanov S; Jones L; Holmans P; Kwak S; Orth M; Ciosi M; Monckton DG; Long JD; Lucente D; Wheeler VC; MacDonald ME; Gusella JF; Lee JM
    J Huntingtons Dis; 2021; 10(3):367-375. PubMed ID: 34180418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CAG Repeats With Long-term Progression in Huntington Disease.
    Langbehn DR; Stout JC; Gregory S; Mills JA; Durr A; Leavitt BR; Roos RAC; Long JD; Owen G; Johnson HJ; Borowsky B; Craufurd D; Reilmann R; Landwehrmeyer GB; Scahill RI; Tabrizi SJ;
    JAMA Neurol; 2019 Nov; 76(11):1375-1385. PubMed ID: 31403680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of extreme motor phenotypes in Huntington's disease.
    Braisch U; Hay B; Muche R; Rothenbacher D; Landwehrmeyer GB; Long JD; Orth M;
    Am J Med Genet B Neuropsychiatr Genet; 2017 Apr; 174(3):283-294. PubMed ID: 27868347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales.
    Sun W; Zhou D; Warner JH; Langbehn DR; Hochhaus G; Wang Y
    J Clin Pharmacol; 2020 Aug; 60(8):1051-1060. PubMed ID: 32416008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.